EICHORCondition: Chronic Lymphocytic Leukaemia · Small Lymphocytic Lymphoma · Hematologic Malignancies · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The goals of this trial are to learn about: * The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of cancer go away.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Has histologically confirmed chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) active disease that is relapsed/refractory (r/r) to prior therapy. * Has confirmed CD19-positive disease. * If human immunodeficiency virus (HIV)-positive, has well-controlled HIV on antiretroviral therapy. * If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load. * If has a history of hepatitis C virus (HCV) infection, has undetectable HCV viral load. Exclusion Criteria: * Has a history of serious cardiovascular and cerebrovascular diseases. * Has a history or presence of central nervous system disease. * Is HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease. * Has a diagnosis of immunodeficiency. * Has a known additional malignancy that is progressing or required active treatment within the past 2 years. * Has active autoimmune disease (not related to underlying leukemia diagnosis) that required systemic treatment in the past 2 years. * Has any active acute graft versus host disease (GvHD) or active chronic GvHD requiring systemic treatment. * Has active infection requiring systemic therapy. * Has not adequately recovered from major surgery or has ongoing surgical complications. * Has a diagnosis of Richter Transformation.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Locations not yet listed on the registry record. |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07709000